OncoMatch/Clinical Trials/NCT07860528
Study on Prostate Salvage Using High-dose-rate Brachytherapy
Official title: Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy
Is NCT07860528 recruiting? Yes, currently enrolling (Oct 2026).
A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Excluded: Stage IV
local recurrence confirmed by next-generation imaging and a positive biopsy; Metastatic disease [excluded]
Prior therapy
Must have received: brachytherapy — initial treatment
Patients whose initial treatment consisted of brachytherapy alone
Must have received: external beam radiotherapy — initial treatment
Patients whose initial treatment consisted of ... external beam radiotherapy
Must have received: external beam radiotherapy with prostate brachytherapy boost — initial treatment
Patients whose initial treatment consisted of ... external beam radiotherapy with a prostate brachytherapy boost
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07860528 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received brachytherapy and external beam radiotherapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages